Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Neil P. Shah, Charles L. Sawyers, John Nicoll et al.|Cancer Cell|2002

Cited by 1.6k